Compare SY & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | ALLO |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 252.9M |
| IPO Year | 2019 | 2018 |
| Metric | SY | ALLO |
|---|---|---|
| Price | $2.91 | $1.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $5.50 | ★ $8.67 |
| AVG Volume (30 Days) | 786.7K | ★ 2.4M |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $201,132,009.00 | N/A |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $51.30 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.67 | $0.86 |
| 52 Week High | $6.28 | $3.78 |
| Indicator | SY | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 52.49 |
| Support Level | $2.78 | $1.38 |
| Resistance Level | $3.00 | $1.57 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.64 | 47.17 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.